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Abstract
Background Catecholamine-producing tumours are called
pheochromocytomas when they are located in the adrenal
gland and sympathetic paragangliomas when they are located
elsewhere in the abdomen. Rarely these tumours do not
produce catecholamines and even more rarely they arise in the
spermatic cord. Over the past decade, systematic mutation
analysis of apparently sporadic cases of pheochromocytomas
and paragangliomas has elucidated the frequent presence of
germ line mutations in one of five candidate genes, including
RET, VHL, SDHB, SDHC, and SDHD.
Clinical history and methods We describe a 45-year-old
man with a non catecholamine-producing paraganglioma of
the spermatic cord. We performed SDHB immunohisto-
chemistry and performed mutation analysis of the SDHB,
SDHC, and SDHD genes.
Results There was no staining of tumour cells with SDHB
immunohistochemistry, indicative of an SDH mutation.
Mutation analysis demonstrated a germ line SDHD mutation
(p.Val147Met).
Conclusions Systematic mutation analysis is required in
paraganglioma patients for the detection of germ line
mutations. This should be preceded by SDHB immunohis-
tochemistry to limit the number of genes to be tested.
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Introduction
Extra-adrenal tumours originating from chromaffin cells are
called sympathetic paragangliomas and arise from para-
ganglia that are distributed along the pre- and paravertebral
sympathetic chains and the sympathetic nerve fibres, which
innervate the pelvic and retroperitoneal organs. In contrast,
tumours originating from the adrenal medulla are called
pheochromocytomas [1]. Between 25% and 79% of
sympathetic paragangliomas and about 90% of pheochro-
mocytomas are associated with clinical signs of excess
catecholamine secretion, while the remaining cases repre-
sent clinically non-functional tumours [2]. Most of these
tumours produce but do not secrete catecholamines and
may therefore evade detection for many years.
The majority of sympathetic paragangliomas occur in
various abdominal sites, mostly in a paravertebral location,
or in the organ of Zuckerkandl, a sympathetic paraganglion
that plays an important role early in life. More rarely,
sympathetic paragangliomas have been described in the
bladder wall, which may elicit micturition-related com-
plaints of excess catecholamine secretion [3, 4]. An even
less frequent location is in the spermatic cord, where until
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now eight cases had been described in the international
literature [5–12]; however, none of these have been
investigated for mutations in sympathetic paraganglioma-
related genes. An overview of the clinical data of these
previous eight patients is presented in Table 1.
Between 12% and 24% of apparently sporadic para-
gangliomas have been shown over the past decade to have a
hereditary basis, involving mutations in one of five
different genes: the REarranged during Transfection (RET)
proto-oncogene, the von Hippel–Lindau (VHL) gene, and
the succinate dehydrogenase subunits B (SDHB), C
(SDHC), and D (SDHD) genes [13], [14].
In the present study, we report the first case of a
spermatic cord sympathetic paraganglioma in which the
tumour tissue was investigated by SDHB immunohisto-
chemistry. This was shown to be a useful tool in diagnosing
paraganglioma patients with SDHx mutations; negative
immunostaining was seen in paragangliomas with SDHx
mutations, whereas paragangliomas without mutations are
positive with SDHB immunohistochemistry [15]. In this
spermatic cord sympathetic paraganglioma, the negative
immunostaining gave an important clue for the presence of
an SDHx mutation, which was subsequently shown to be a
previously unknown germ line SDHD mutation.
Clinical history
A 45-year-old man presented with a painless lump in his
left hemiscrotum of months’ duration. In his past medical
history, an episode of acute left epididymitis, which
subsided with antibiotics, was recorded 20 years earlier.
On physical examination, a palpable, painless, firm mass
was revealed in the upper pole of this left testicle. With a
provisional diagnosis of a testicular neoplasm, a left
inguinal orchiectomy was recommended and subsequently
performed. His blood pressure was stable during and after
surgery. The orchiectomy specimen displayed a tumour
mass confined to the spermatic cord measuring 4.8×3.3×
2.5 cm, weighing 71 g, surrounded by a capsule. The cut
surface showed homogeneously reddish-white tumour
tissue with an elastic consistency, while both the testis
and epididymis were of normal colour, shape, and
consistency (Fig. 1a).
Microscopically, there was a solid-looking tumour, with
well-defined nests or trabeculae of tumour cells, separated
by highly vascularized septa, focally thickened and hyali-
nized (Fig. 1b). Immunohistochemically, the tumour cells
displayed strong and diffuse reactivity for vimentin, chro-
mogranin A (Fig. 1c), synaptophysin, and neuron-specific
enolase. Moreover, sustentacular cells were immunoreactive
for S-100 protein. Taken together, a diagnosis of an
abdominal, presumably sympathetic, paraganglioma was
proffered. Following this histological diagnosis, the urolo-
gists performed an additional 24-h urinary analysis of
catecholamines and their metabolites, which was shown to
be normal. Three years after surgery, the patient is healthy,
free of disease, and without tumours at other anatomic
sites. There were no other family members known to the
patient that had one or more pheochromocytomas or
paragangliomas.
Material and methods
DNA was isolated from formalin fixed paraffin-embedded
(FFPE) material. A region of at least 80% tumour cells was
micro-dissected, and DNA was isolated using the Puregene
DNA isolation kit (Gentra, Minneapolis, USA) according to
manufacturer’s protocol. An SDHB immunohistochemistry
was performed using the rabbit polyclonal antibody
HPA002868 (Sigma-Aldrich Corp, St. Louis, MO; 1:500)
according to the method described by van Nederveen et al.
[15]. Subsequently, mutation analysis was performed by
direct sequencing of tumour tissue.
Results
The SDHB immunohistochemistry did not show any
reactivity of the neoplastic cells (Fig. 1d). The mutation
Table 1 Clinical data of the previous eight patients with spermatic cord PGL
Age Symptoms Hormonally active Additional tumours Reference
1 37 Painless mass right scrotal sac for 10 years No No Eusebi et al. [5]
2 52 Painless mass left scrotal sac for
10 years/elevated blood pressure at operation
Yes No Soejima et al. [6]
3 18 Painless mass in right scrotal sac for 2 years No No Bacchi at al. [7]
4 37 Painful mass in right scrotal sac No No Mashat et al. [8]
5 40 Painless mass in left scrotal sac No No Attaran et al. [9]
6 52 Lump within the right spermatic cord No No Young et al. [10]
7 55 Painless left scrotal mass Yes Bilateral carotid body paragangliomas
and bilateral pheochromocytomas
Abe et al. [11]
8 69 Weight loss, malaise, and mass in right testicle No No Garaffa et al. [12]
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analysis that was performed by direct sequencing, on
tumour tissue of this patient, showed an SDHD mutation
in exon 4 (c.439 G→T, p.Val147Met) (Fig. 1e).
Discussion
In the present case report, we have described, for the first
time in an individual case the use of SDHB immunohisto-
chemistry for the guidance of subsequent DNA mutation
analysis. Because of negative immunostaining, an SDHx
mutation was predicted and eventually shown to be a p.
Val147Met SDHD mutation.
This patient represents the ninth patient in the English
literature with a spermatic cord paraganglioma, which was
detected by its local mass effect, as it did not appear to produce
catecholamines. The latter has not been formally proven, as no
biochemical analyses had been carried out prior to surgery;
however, the patient did not report any complaints that could
be related to high blood pressure and/or catecholamine excess.
The unusual location for a paraganglioma in the spermatic
cord has been attributed to migration of neural crest progenitor
cells, which are known to be present in the paraganglia
throughout the abdomen, as is reflected by the various
locations of abdominal sympathetic paraganglioma [16]. It
is entirely conceivable that these progenitor cells migrate
along with the developing male gonad and give rise to
paragangliomas at low frequency.
Thus far, these paragangliomas have been described in
middle-aged men, none of whom has had genetic testing,
although one patient clearly had evidence ofmultiple tumours,
for which we would strongly recommend systematic candi-
Fig. 1 a Gross aspect of sper-
matic cord paraganglioma. b
Typical histology of the tumour
showing large polygonal cells
with ample amphophilic
cytoplasm and moderate nuclear
pleomorphism. c Chromogranin
A immunohistochemistry
showing positive staining in the
tumour cells. d SDHB
immunohistochemistry showing
negative staining in tumour
cells, while endothelial cells are
immunoreactive. e Mutation
analysis showing a p.Val147Met
mutation in the tumour DNA
compared with normal reference
DNA
Virchows Arch (2010) 457:619–622 621
date gene mutation analysis [11]. Until about 10 years ago,
pheochromocytomas and paragangliomas were known to
occur in the context of various tumour syndromes, including
multiple endocrine neoplasia type 2 (MEN 2), VHL disease,
and NF1. Since the beginning of this decade, four additional
genes (SDHB, SDHC, SDHD, and SDHAF2) have been
added, causing the pheochromocytoma–paraganglioma
syndrome, characterized by the occurrence of multiple
pheochromocytoma and/or paraganglioma in the same
patient and his or her family members. Whereas originally
the frequency of germ line mutations in pheochromocytomas
and paragangliomas was estimated at 10%, based upon
patients from clearly recognizable familial tumour syndromes,
systematic analysis of all genes (with the exception of NF1)
has shown that an additional 15–25% of pheochromocytoma
and paraganglioma patients are carriers of germ line
mutations in each of these genes [13, 14]. Although somatic
mutations in some of these genes have been described, they
are quantitatively insignificant [4].
The finding of this mutation has important implications for
further patient management, as it is known that patients with
SDHD germ line mutations are at increased risk to develop
further paragangliomas, either abdominal or head and neck, or
even pheochromocytomas. In addition, other family members
may also be affected, so they should be screened too.
Taken together, we show here that the spermatic cord can be
a rare location for the occurrence of paragangliomas in male
patients and that a stepwise immunohistochemical and genetic
approach can be employed for the diagnosis of inherited
paraganglioma, even in the absence of a positive family history.
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